Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. It is characterized by inflammation, demyelination, and neurodegeneration, which can lead to a wide range of symptoms such as muscle weakness, fatigue, vision problems, and cognitive impairment. MS is a progressive disease, and there is currently no cure for it. However, there are several medications available that can help manage the symptoms and slow down the progression of the disease.
One of the most promising medications for relapsing MS is Sanofi’s Aubagio (teriflunomide). Aubagio is an oral medication that works by inhibiting the proliferation of immune cells that attack the myelin sheath, which protects the nerve fibers in the brain and spinal cord. By reducing the inflammation and demyelination, Aubagio can effectively decrease disease activity in patients with relapsing MS.
Several clinical trials have demonstrated the efficacy of Aubagio in reducing the frequency and severity of relapses, as well as slowing down the progression of disability. In a phase III trial called TEMSO, Aubagio reduced the annualized relapse rate by 31% compared to placebo. In another phase III trial called TOWER, Aubagio reduced the risk of disability progression by 36% compared to placebo.
Aubagio is also well-tolerated by most patients, with few serious side effects. The most common side effects include diarrhea, nausea, hair loss, and elevated liver enzymes. However, these side effects are usually mild and transient, and can be managed with dose adjustments or supportive care.
Aubagio is approved by the US Food and Drug Administration (FDA) for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is also approved by the European Medicines Agency (EMA) and other regulatory agencies around the world.
In conclusion, Sanofi’s Aubagio is a highly effective medication for the treatment of relapsing MS. It can reduce disease activity, slow down disability progression, and improve the quality of life for patients with this debilitating disease. If you or a loved one has been diagnosed with relapsing MS, talk to your healthcare provider about whether Aubagio may be a suitable treatment option for you.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.